{"abstract":"The National Institute of Neurological Disorders and Stroke (\"NINDS\"), an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive, sublicensable patent license to University College London Business, Ltd. (\"UCLB\"), incorporated in England and Wales under company registration number 02776963 whose registered office address is University College London, Gower Street, London WC1E 6BT, United Kingdom, for NINDS's rights to the patent applications listed in the Supplementary Information section of this notice. UCLB is the technology transfer company of the University College London (\"UCL\"), a non-profit research institution located in London, United Kingdom.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2023/02/09/2023-02772.html","cfr_references":[],"citation":"88 FR 8440","comment_url":null,"comments_close_on":"2023-02-24","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Institute of Neurological Disorders and Stroke Technology Transer Office by February 24, 2023 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2023-02772","effective_on":null,"end_page":8441,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2023/02/09/2023-02772.xml","html_url":"https://www.federalregister.gov/documents/2023/02/09/2023-02772/prospective-grant-of-exclusive-patent-license-novel-therapeutics-for-the-treatment-of","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2023-02772?publication_date=2023-02-09","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2023-02-09/2023-02772/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":159,"last_updated":"2026-09-20 22:15:05 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2023-02-09/pdf/2023-02772.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2023-02772.pdf?1675863930","publication_date":"2023-02-09","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2023/02/09/2023-02772.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-24T23:46:07Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":8440,"subtype":null,"title":"Prospective Grant of Exclusive Patent License: Novel Therapeutics for the Treatment of Neurodegenerative Disorders","toc_doc":"Prospective Grant of Exclusive Patent License: Novel Therapeutics for the Treatment of Neurodegenerative Disorders","toc_subject":"Licenses; Exemptions, Applications, Amendments etc.:\n","topics":[],"type":"Notice","volume":88}